Calif. Jury Awards $34.21M to Plaintiff in J&J Baby Powder Mesothelioma Case

Johnson & Johnson's icotrokinra (Icotyde) showed improvement in psoriatic arthritis (PsA) symptoms at 16 weeks in a phase 3 trial, with 200-mg and 400-mg doses outperforming placebo. The drug, approved for psoriasis, is being studied for PsA, with no new safety signals identified. Experts highlight its potential as an oral treatment option. The trial compared icotrokinra to ustekinumab, with results showing efficacy and safety. Final 52-week data are pending.

Johnson & Johnson's Icotyde pill showed improvement in psoriatic arthritis symptoms in a Phase 3 trial, with 58% of patients on the drug achieving at least 20% improvement compared to 41% on placebo. The drug is not yet approved for this use, and full safety data are pending. The company plans further trials, with results expected in 2027.

JNJ-6143, an oral androgen receptor-targeted RIPTAC, showed promising activity in a phase 1 study for metastatic castration-resistant prostate cancer. At 50 mg daily, it achieved 71% PSA50 and 41% PSA90 response rates, with partial responses in measurable disease. The drug demonstrated tolerability and efficacy across high-risk genomic subgroups, supporting further development.

Johnson & Johnson reported that its Phase 3 trial (Study 452) for CAPLYTA in adults with bipolar I mania met primary and key secondary endpoints. This is the second pivotal Phase 3 study for the drug to achieve its goals. The trial tested CAPLYTA during manic episodes, with or without mixed features.

Johnson & Johnson's JNJ-6143, a novel RIPTAC molecule, showed promising results in a phase 1 trial for metastatic castration-resistant prostate cancer. The drug demonstrated high PSA response rates (77% PSA 50, 48% PSA 90) and a 75% confirmed ORR in measurable disease, with no high-grade treatment-related adverse events at the 50 mg dose. The trial included heavily pretreated patients, with a median of four prior systemic therapies.

Johnson & Johnson (JNJ) reported positive results from its Phase 3 trial of CAPLYTA for bipolar I disorder, meeting primary and secondary endpoints. The therapy showed significant improvement in manic symptoms and illness severity compared to placebo. JNJ plans to use these results for U.S. regulatory submission. Shares were down 1.25% at $277.26 at the time of publication.